News >

Radium-223 Plus Anti-VEGF Therapy Reduces Bone Turnover in Advanced RCC

Published: Tuesday, Sep 26, 2017

The safety analysis included all 30 patients (15 in each group). The most common grade 3/4 adverse events with pazopanib were elevated liver-enzymes (ALT, 20%; AST, 14%), proteinuria, elevated serum amylase, and hypertension (13% each). In the sorafenib group, rash was most common (20%); grade 3/4 anemia, fatigue, serum amylase, hand-foot syndrome, and hypertension each occurred in 1 patient.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication